Innovation Pharmaceuticals Inc (IPIX)

[BioTechMaven]

The conference is a major milestone that kicks of IPIX data reveal 3Q17 season in style. As we have already seen the cohort 1 and 2 data, which has been remarkable to date, we have not seen the much hyped (and assuming worthwhile so) endoscopic images and evidence (the gold standard in the IBD world). July 10 is a substantial milestone not in likely getting deviant cohort 3 news, but rather a public signal that a) Phase 2 trial is done. B) PoC mandate clearly achieved. C) remarkable responses with a basic delivery (emema) D) only
More efficacy ahead with delivery switch E) trial is safe, mimicking safety in OM and absssi trials (meaning, Brilacidin is safe) F) let's see that much hyped endoscopic evidence---dying too---as plenty of many billion dollar IBD deals were coy on this evidence (afraid to show patient healing)

And most importantly (g) the Phase 2 trial's conclusion is: the a critical milestone for pharma's. Pharma's love topline data.

We enter partnership season. There's no going back...are you ready?